You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

CLINICAL TRIALS PROFILE FOR CYCLOPENTOLATE HYDROCHLORIDE


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for CYCLOPENTOLATE HYDROCHLORIDE

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00348166 ↗ Does Undercorrection of Myopia Retard Myopia Progression Among Kindergarten Children? Withdrawn KK Women's and Children's Hospital Phase 1 2005-12-01 The purpose of this study is to find out if undercorrection of myopia slow down the progression of myopia in kindergarten children.
NCT01170130 ↗ Lidocaine Usage for Pupil Dilatation (Mydriasis) Completed Carmel Medical Center N/A 2009-12-01 The purpose of this study is to determine if the mydriatic effect of intracameral lidocaine 1% is as effective as topical cyclopentolate 1% and phenylephrine 10% for achieving effective mydriasis during phacoemulsification surgery.
NCT02177539 ↗ A New More Efficient Cycloplegia Scheme Unknown status Pontificia Universidad Catolica de Chile Phase 4 2014-05-01 The purpose of this study is to determine whether tropicamide + phenylephrine cyclopentolate + applied for once waiting 30 minutes to retinoscopy (new scheme) is not inferior to apply cyclopentolate alone and wait 45 minutes to retinoscopy (traditional scheme)
NCT02309385 ↗ Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis Completed National Eye Institute (NEI) Phase 1/Phase 2 2014-10-01 The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.
NCT02309385 ↗ Safety and Efficacy Study of DSP-Visulex for the Treatment of Anterior Uveitis Completed Aciont Inc Phase 1/Phase 2 2014-10-01 The purpose of this study is to determine the efficacy, safety, and tolerability of dexamethasone sodium phosphate Visulex (DSP-Visulex) after repeated-dose administration in patients with acute anterior uveitis.
NCT02895035 ↗ Comparison of Epinephrine and Phenylephrine/Ketorolac With Regards to Pupil Size Terminated Milton S. Hershey Medical Center Phase 4 2016-09-01 The objective of this study is to compare the maintenance of intraoperative mydriasis during cataract surgery between two drugs: epinephrine, which has routinely been used for decades, and Omidria, a newly FDA approved combination drug of phenylephrine and ketorolac. Patients undergoing cataract surgery that are enrolled in the trial will randomly receive one of the drugs in one eye, and the other eye will receive the drug during the subsequent cataract surgery.
NCT03508817 ↗ Atropine 0.01% Eye Drops in Myopia Study Enrolling by invitation Christian Medical College, Vellore, India Early Phase 1 2018-12-20 Control of myopia progression has become an important goal because of concerns regarding significantly increased risks of retinal degeneration, retinal detachment, glaucoma and cataract associated with high myopia. It is also clear there prevalence of myopia in children and young adults is increasing all over the world. Several methods including use of progressive addition lenses, rigid gas-permeable contact lenses, and life-style modifications (increased outdoor activity) have reported to alter myopia progression with varying efficacy. In general they have yielded clinical results of marginal significance. Atropine sulphate eye drops has consistently been demonstrated to inhibit axial myopia progression in both humans and animal models. Yet it has not found widespread clinical application for myopia control due to ocular side-effects of cycloplegia and pupil dilation. Recently 0.01% atropine has been shown to be effective in arresting myopia progression without side-effects of cycloplegia and near vision impairment and pupil dilatation and increased light sensitivity. Almost all studies on atropine have been carried out on children of Chinese origin. Efficacy (concentration and dosing) and safety need to be established in the population of interest, before routine use can be recommended. We plan to evaluate the efficacy and safety of topical 0.01% atropine eye drops in slowing the progression of myopia and ocular axial elongation in Omani children. A total of 150 children of ages 6-16 years will be randomized to two groups. Intervention group will receive atropine 0.01% once daily in each eye for two years (Phase 1). Control group will not receive any medications. Follow up visits will be scheduled every three months in Phase 1. Subsequently, medication will be stopped and the study patients will be followed up every six months for one year (Phase 2). The progression of myopia (change in refractive error and axial length) will be compared in the two groups by objective methods.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for CYCLOPENTOLATE HYDROCHLORIDE

Condition Name

Condition Name for CYCLOPENTOLATE HYDROCHLORIDE
Intervention Trials
Cataract 3
Refractive Errors 2
Cycloplegia 2
Non-Infectious Anterior Uveitis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for CYCLOPENTOLATE HYDROCHLORIDE
Intervention Trials
Mydriasis 3
Cataract 3
Refractive Errors 3
Myopia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for CYCLOPENTOLATE HYDROCHLORIDE

Trials by Country

Trials by Country for CYCLOPENTOLATE HYDROCHLORIDE
Location Trials
United States 5
Jordan 2
Oman 1
Egypt 1
Chile 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for CYCLOPENTOLATE HYDROCHLORIDE
Location Trials
Utah 1
Texas 1
North Dakota 1
North Carolina 1
Massachusetts 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for CYCLOPENTOLATE HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for CYCLOPENTOLATE HYDROCHLORIDE
Clinical Trial Phase Trials
Phase 4 6
Phase 3 1
Phase 1/Phase 2 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for CYCLOPENTOLATE HYDROCHLORIDE
Clinical Trial Phase Trials
Completed 5
Unknown status 2
Terminated 1
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for CYCLOPENTOLATE HYDROCHLORIDE

Sponsor Name

Sponsor Name for CYCLOPENTOLATE HYDROCHLORIDE
Sponsor Trials
Islamic Hospital, Jordan 2
Aciont Inc 1
Milton S. Hershey Medical Center 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for CYCLOPENTOLATE HYDROCHLORIDE
Sponsor Trials
Other 15
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.